U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H32N2O
Molecular Weight 316.4809
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-5207852

SMILES

C(COC1=CC=C(CN2CCCCC2)C=C1)CN3CCCCC3

InChI

InChIKey=PTKHFRNHJULJKT-UHFFFAOYSA-N
InChI=1S/C20H32N2O/c1-3-12-21(13-4-1)16-7-17-23-20-10-8-19(9-11-20)18-22-14-5-2-6-15-22/h8-11H,1-7,12-18H2

HIDE SMILES / InChI

Molecular Formula C20H32N2O
Molecular Weight 316.4809
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including

JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at human (pKi=9.24) H3 receptor and was developed by Johnson & Johnson Pharmaceutical. During preclinical studies were shown that JNJ-5207852 might be useful in the treatment of cognitive impairment in epilepsy. On animal models was discovered, that this compound readily penetrates the brain tissue after subcutaneous administration.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mouse. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.24 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.
2004 Nov
Patents

Sample Use Guides

in rats: On day 1 and following an overnight fast, animals were weighed (body weight range: 258–307 g) and each formulation was administered to a group of four male and four female rats. The i.v. formulation was administered by jugular venipuncture at a dose volume of 2 ml kg−1. The oral formulation was administered by gavage at a dose volume of 2 ml kg−1. Following dose administration, blood samples (0.25–0.40 ml) were collected from each animal by jugular venipuncture under isoflurane anesthesia. Blood samples were collected (using lithium heparin as the anticoagulant) at pre-dose and again at 0.08 (i.p. only), 0.25 (oral only), 0.33 (i.p. only), 0.5 (oral only), 1, 2, 4, 8, and 24 h post-dose.
Route of Administration: Other
Binding of 3H-JNJ-5207852 to rat H3 receptor were studied. Membranes from rat brain were incubated with increasing concentrations of 3H-JNJ-5207852 (0-70 nM)
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:06:14 UTC 2023
Edited
by admin
on Sat Dec 16 09:06:14 UTC 2023
Record UNII
4I9OVB1G7D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
JNJ-5207852
Common Name English
PIPERIDINE, 1-(3-(4-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL)-
Systematic Name English
1-(3-(4-((PIPERIDIN-1-YL)METHYL)PHENOXY)PROPYL)PIPERIDINE
Systematic Name English
Code System Code Type Description
WIKIPEDIA
JNJ-5207852
Created by admin on Sat Dec 16 09:06:14 UTC 2023 , Edited by admin on Sat Dec 16 09:06:14 UTC 2023
PRIMARY
EPA CompTox
DTXSID70377579
Created by admin on Sat Dec 16 09:06:14 UTC 2023 , Edited by admin on Sat Dec 16 09:06:14 UTC 2023
PRIMARY
PUBCHEM
2766326
Created by admin on Sat Dec 16 09:06:14 UTC 2023 , Edited by admin on Sat Dec 16 09:06:14 UTC 2023
PRIMARY
CAS
398473-34-2
Created by admin on Sat Dec 16 09:06:14 UTC 2023 , Edited by admin on Sat Dec 16 09:06:14 UTC 2023
PRIMARY
FDA UNII
4I9OVB1G7D
Created by admin on Sat Dec 16 09:06:14 UTC 2023 , Edited by admin on Sat Dec 16 09:06:14 UTC 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY